Innate Pharma SA

Innate Pharma SA reported its third quarter 2026 business and financial update. Key developments include upcoming presentations of Phase 1 data for IPH4502, progress in lacutamab trials with a planned FDA filing in H2 2027, and an expected readout for the AstraZeneca-led PACIFIC-9 Phase 3 trial in H1 2027. The company reported a cash position of €96.8 million as of September 30, 2026, with a cash horizon extending to Q1 2028. Additionally, Frédéric Lombard, CFO, will step down on December 31, 2026.

Innate Pharma SA announced a strategic partnership with Sobi to license lacutamab, an anti-KIR3DL2 antibody for T-cell lymphoma. Under the agreement, Sobi will pay Innate Pharma $75 million upfront, with potential for up to $465 million in future regulatory and commercial milestones, plus tiered double-digit royalties on net sales. This partnership will enable the initiation of the TELLOMAK-3 Phase 3 study, a key step towards accelerated approval for lacutamab in Sézary syndrome. Additionally, Innate Pharma appointed Markus Jensen as its new Chief Medical Officer, effective September 1, 2026.

Innate Pharma SA announced its participation in a panel discussion titled 'Changing Treatment Landscape in Bladder Cancer' at the BTIG Virtual Biotechnology Conference on July 28, 2026. The company, a clinical-stage biotechnology firm, specializes in developing immunotherapies for cancer patients, leveraging its expertise in antibody-engineering and innovative target identification. Its pipeline includes differentiated assets like IPH4502, lacutamab, and monalizumab, and it maintains collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca.

Innate Pharma SA announced the completion of enrollment in the dose escalation part of its Phase 1 study for IPH4502, a novel Nectin-4 exatecan ADC. Preliminary data from 76 patients are anticipated by year-end 2026. The study has shown a favorable safety profile with limited hematological toxicity and observed objective responses in heavily pre-treated patients with urothelial carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma.

Innate Pharma SA announced the voting results from its Annual General Meeting (AGM) held on May 21, 2026, in Marseille. Shareholders approved all resolutions presented at the meeting. The AGM saw a quorum of 37.136%, with 94 votes cast out of 34,872,293 shares.

Innate Pharma SA announced its participation in the Jefferies Global Healthcare Conference 2026, scheduled from June 2–4, 2026, in New York, United States. The company will hold one-on-one investor meetings during the event. Innate Pharma is a clinical-stage biotechnology company focused on developing immunotherapies for cancer patients, leveraging its expertise in antibody-engineering and innovative target identification.

Innate Pharma provided its Q1 2026 business update, highlighting significant progress across its clinical pipeline. The confirmatory Phase 3 TELLOMAK-3 trial for lacutamab is planned for H2 2026, contingent on securing non-dilutive financing. The IPH4502 Nectin-4 ADC showed preliminary anti-tumor activity with a favorable safety profile, nearing completion of Phase 1 enrollment. Additionally, the PACIFIC-9 Phase 3 trial for monalizumab is on track for a H2 2026 data readout, and IPH5201 demonstrated encouraging interim results in the MATISSE Phase 2 study for NSCLC. The company reported a cash position of €25.4 million as of March 31, 2026, with an anticipated cash runway until the end of Q3 2026.

Innate Pharma SA announced its total number of shares outstanding and voting rights as of April 16, 2026, in accordance with French regulations. The company reported 93,934,210 shares outstanding, with 93,921,863 theoretical voting rights and 93,903,288 exercisable voting rights. This update provides transparency on the company's capital structure.

Innate Pharma SA announced details for an upcoming live webcast and conference call. The event will feature key executives including the CEO, CMO, COO, VP of Investor Relations, and CFO. Participants can join via a provided webcast link or telephone registration, with a replay available on the company's website for 90 days.